Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 02 Nov 2017 Planned End Date changed from 15 Mar 2018 to 16 Mar 2018.
- 02 Nov 2017 Planned primary completion date changed from 15 Mar 2018 to 16 Mar 2018.
- 02 Nov 2017 Status changed from not yet recruiting to recruiting.